Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors
نویسندگان
چکیده
منابع مشابه
JAK inhibitors and myelofibrosis, Einstein and ruxolitinib.
This year marks a decade since the original descriptions of the JAK2 mutation in myeloproliferative neoplasms. 4 In the intervening years we have witnessed this finding influencing diagnostic processes, prognostic determination and more recently therapeutics. Whilst some perhaps naively anticipated that the benefits of JAK2 as a therapeutic target would parallel those of BCR/ABL inhibitors we h...
متن کاملJAK-STAT pathway and JAK inhibitors: a primer for dermatologists
Background: All cellular events depend upon the DNA synthesis and gene expression involving complex interplay between ligands such as interleukins and interferons, with various cell membrane receptors. These ligand-receptors interactions transmit signals within the cell via numerous signal transduction pathways to affect gene expression. Janus kinase/signal transducer and activator of transcrip...
متن کاملAllogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it is neither curative...
متن کاملTreatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Myelofibrosis (MF) can present as a primary disorder or evolve from polycythemia vera (PV) or essential thrombocythemia (ET) to post-PV MF or post-ET MF, respectively. MF is characterized by bone marrow fibrosis, splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis, and a collection of debilitating symptoms. Until recently, the therapeutic options for patients with MF consisted of ...
متن کاملNovel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
Despite advances in the treatment of HIV infection with ART, elucidating strategies to overcome HIV persistence, including blockade of viral reservoir establishment, maintenance, and expansion, remains a challenge. T cell homeostasis is a major driver of HIV persistence. Cytokines involved in regulating homeostasis of memory T cells, the major hub of the HIV reservoir, trigger the Jak-STAT path...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2018
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2018-99-115408